Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity

Neutrophil serine proteases (NSPs) are activated by dipeptidyl peptidase 1 (DPP1) during neutrophil maturation. The effects of neutrophil turnover rate on NSP activity following DPP1 inhibition was studied in a rat pharmacokinetic/pharmacodynamic model.

[1]  Christopher Southan,et al.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes , 2015, British journal of pharmacology.

[2]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..

[3]  John C McGrath,et al.  Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP , 2015, British journal of pharmacology.

[4]  R. Stockley,et al.  α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[5]  F. Nielsen,et al.  Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses. , 2014, The Journal of clinical investigation.

[6]  R. Austin,et al.  Cathepsin C inhibitors: property optimization and identification of a clinical candidate. , 2014, Journal of medicinal chemistry.

[7]  N Benson,et al.  Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.

[8]  S. Bekkering,et al.  Another look at the life of a neutrophil , 2013 .

[9]  P. Kubes,et al.  Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.

[10]  E. Arámbula-Meraz,et al.  Identification of novel mutation in cathepsin C gene causing Papillon-Lefèvre Syndrome in Mexican patients , 2013, BMC Medical Genetics.

[11]  K. Forsman-Semb,et al.  Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis , 2012, European Respiratory Journal.

[12]  A. Churg,et al.  AZD9668: Pharmacological Characterization of a Novel Oral Inhibitor of Neutrophil Elastase , 2011, Journal of Pharmacology and Experimental Therapeutics.

[13]  Robert J Riley,et al.  Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption , 2011, Drug Metabolism and Disposition.

[14]  J. Unitt,et al.  Development and Validation of a Simple Cell-Based Fluorescence Assay for Dipeptidyl Peptidase 1 (DPP1) Activity , 2011, Journal of biomolecular screening.

[15]  M. Horwitz,et al.  Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases , 2010, Pharmacological Reviews.

[16]  H. L. Wright,et al.  Neutrophil function in inflammation and inflammatory diseases. , 2010, Rheumatology.

[17]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[18]  J. Borghans,et al.  In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. , 2010, Blood.

[19]  M. Percival,et al.  Therapeutic utility and medicinal chemistry of cathepsin C inhibitors. , 2010, Current topics in medicinal chemistry.

[20]  Christopher Haslett,et al.  Neutrophil Apoptosis: Relevance to the Innate Immune Response and Inflammatory Disease , 2010, Journal of Innate Immunity.

[21]  Yuichi Sugiyama,et al.  Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development , 2009, The AAPS Journal.

[22]  N. Méthot,et al.  In Vivo Inhibition of Serine Protease Processing Requires a High Fractional Inhibition of Cathepsin C , 2008, Molecular Pharmacology.

[23]  N. Méthot,et al.  Inhibition of the Activation of Multiple Serine Proteases with a Cathepsin C Inhibitor Requires Sustained Exposure to Prevent Pro-enzyme Processing* , 2007, Journal of Biological Chemistry.

[24]  R J Riley,et al.  Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. , 2007, Current drug metabolism.

[25]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[26]  Iftekhar Mahmood,et al.  Interspecies scaling of biliary excreted drugs: a comparison of several methods. , 2005, Journal of pharmaceutical sciences.

[27]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[29]  U. Gullberg,et al.  Characterization of the processing and granular targeting of human proteinase 3 after transfection to the rat RBL or the murine 32D leukemic cell lines , 1997, Journal of leukocyte biology.

[30]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[31]  R. Stockley.  The role of proteinases in the pathogenesis of chronic bronchitis. , 1994, American journal of respiratory and critical care medicine.

[32]  P. Lipsky,et al.  Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. , 1993, The Journal of biological chemistry.

[33]  S. Rennard,et al.  Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. , 1990, The American review of respiratory disease.

[34]  V. Ferrans,et al.  Expression of the neutrophil elastase gene during human bone marrow cell differentiation , 1989, The Journal of experimental medicine.

[35]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[36]  L. Harker,et al.  Neutrophil kinetics in man. , 1976, The Journal of clinical investigation.

[37]  Muksinova Kn,et al.  Kinetics of cell populations in the maturing nondividing neutrophil compartment of rat bone marrow , 1976 .

[38]  Muksinova Kn,et al.  [Kinetics of cell populations in the compartment of maturing, non-dividing neutrophils of rat bone marrow]. , 1976 .

[39]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[40]  V. V. Sukhodoev,et al.  [Kinetics of cell populations in the compartment of maturing, non-dividing neutrophils of rat bone marrow]. , 1976, Biulleten' eksperimental'noi biologii i meditsiny.